Ticker LaunchIPO · RNA
Avidity Biosciences, Inc.
Formerly Avidity Biosciences LLC; Avidity NanoMedicines LLC
Avidity Biosciences, Inc. (RNA) priced its initial public offering on Jun 12, 2020 at $18.00 per share, raising $259.2M, and listed on Nasdaq Global Market. At the IPO price its market capitalization was about $636.3M. Latham & Watkins advised the company and Cooley advised the underwriters.
Avidity Biosciences, Inc. develops Antibody Oligonucleotide Conjugates, a class of therapies combining the tissue selectivity of monoclonal antibodies with oligonucleotide precision. It is first targeting muscle diseases, and its lead candidate, AOC 1001, is for myotonic dystrophy type 1, with an IND planned for 2021.
- Status
- IPO
- Ticker
- RNA
- Exchange
- Nasdaq Global Market
- Priced
- Jun 12, 2020
- IPO price
- $18.00
- Raised
- $259.2M
- Market cap at IPO price
- $636.3M
- First filed
- May 22, 2020
- Company counsel
- Latham & Watkins
- Underwriters' counsel
- Cooley
- Sector
- Biotech & pharma
- Country / state
- CA
Market cap at IPO price = shares outstanding after the offering (all classes, before the over-allotment option) × the IPO price, from the final prospectus.
More on this listing for subscribers
- Lock-up period and expiry date
- Shares offered, over-allotment and shares outstanding after the offering
Every record in the database also has its full filing timeline, a daily-updated calendar, watchlist alerts and Excel export.
Then $99/month or $999/year. Cancel anytime.
Filings
- Registration statement (S-1) first filed May 22, 2020
- Latest amendment Jun 11, 2020
- Final prospectus (424B4) Jun 12, 2020
- All filings on EDGAR CIK 1599901
Other Biotech & pharma IPOs in 2020
- Royalty Pharma plcRPRX · Jun 17, 2020 · $2.18B
- Vaxcyte, Inc.PCVX · Jun 15, 2020 · $250M
- Generation Bio Co.Jun 12, 2020 · $200M
- Lantern Pharma Inc.LTRN · Jun 12, 2020 · $26.2M
- Calliditas Therapeutics ABCALTX · Jun 8, 2020
- Legend Biotech CorpLEGN · Jun 8, 2020 · $423.8M